(Q34039406)

30 July 2017

Bruton's tyrosine kinase (BTK) inhibitors in clinical trials (English)

1 reference

30 July 2017

Jan A Burger

1

1 reference

30 July 2017

1 March 2014

1 reference

Current hematologic malignancy reports

30 July 2017

1 reference

30 July 2017

9

1 reference

30 July 2017

1

1 reference

30 July 2017

44-49

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-013-0188-8

30 July 2017

0 references

cites work

The B cell antigen receptor controls integrin activity through Btk and PLCgamma2.

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Tec tyrosine kinase links the cytokine receptors to PI-3 kinase probably through JAK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Expression of Bruton's tyrosine kinase protein within the B cell lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Primary B cell immunodeficiencies: comparisons and contrasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

B cell antigen receptor signaling: roles in cell development and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Mechanisms of B-cell lymphoma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Nurture versus nature: the microenvironment in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

B-cell receptor signaling in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

The B-cell receptor signaling pathway as a therapeutic target in CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Oncogenic CARD11 mutations in human diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Targeted covalent drugs of the kinase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

Bruton's Tyrosine Kinase and Phospholipase Cγ2 Mediate Chemokine-Controlled B Cell Migration and Homing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0188-8

The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective

21 January 2018

1 reference

12 December 2020

Association and activation of Btk and Tec tyrosine kinases by gp130, a signal transducer of the interleukin-6 family of cytokines

1 reference

12 December 2020

Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]

1 reference

12 December 2020

Are Erk, Btk, and PECAM-1 major players in GPIb signaling? The challenge of unraveling signaling events downstream of platelet GPIb

1 reference

12 December 2020

A novel chronic lymphocytic leukemia subset expressing mutated IGHV3-7-encoded rheumatoid factor B-cell receptors that are functionally proficient

1 reference

12 December 2020

Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13).

1 reference

12 December 2020

Survival of leukemic B cells promoted by engagement of the antigen receptor

1 reference

12 December 2020

10.1007/S11899-013-0188-8

Identifiers

DOI

1 reference

PubMed ID

24357428

Dimensions Publication ID

30 July 2017

0 references

1 reference

PubMed ID

24357428